01440nas a2200181   4500000000100000000000100001008004100002260000900043100001700052700002100069700002000090245016600110856005800276300001200334490000700346520088900353022001601242       2018                            d  c20181 aHana Golding1 aSurender Khurana1 aMarina Zaitseva00aWhat Is the Predictive Value of Animal Models for Vaccine Efficacy in Humans? The Importance of Bridging Studies and Species-Independent Correlates of Protection  uhttp://cshperspectives.cshlp.org/content/10/4/a028902  aa0289020 v103 aAnimal models have played a pivotal role in all stages of vaccine development. Their predictive value for vaccine effectiveness depends on the pathogen, the robustness of the animal challenge model, and the correlates of protection (if known). This article will cover key questions regarding bridging animal studies to efficacy trials in humans. Examples include human papillomavirus (HPV) vaccine in which animal protection after vaccination with heterologous prototype virus-like particles (VLPs) predicted successful efficacy trials in humans, and a recent approval of anthrax vaccine in accordance with the “Animal Rule.” The establishment of animal models predictive of vaccine effectiveness in humans has been fraught with difficulties with low success rate to date. Challenges facing the use of animal models for vaccine development against Ebola and HIV will be discussed.  a, 1943-0264